[go: up one dir, main page]

WO1996000503B1 - Nouveaux peptides - Google Patents

Nouveaux peptides

Info

Publication number
WO1996000503B1
WO1996000503B1 PCT/US1995/008156 US9508156W WO9600503B1 WO 1996000503 B1 WO1996000503 B1 WO 1996000503B1 US 9508156 W US9508156 W US 9508156W WO 9600503 B1 WO9600503 B1 WO 9600503B1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
ser
sequence
amino acids
oligopeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/008156
Other languages
English (en)
Other versions
WO1996000503A1 (fr
Filing date
Publication date
Priority claimed from US08/267,092 external-priority patent/US5599686A/en
Priority to SK1640-96A priority Critical patent/SK164096A3/sk
Priority to BR9508151A priority patent/BR9508151A/pt
Priority to NZ290239A priority patent/NZ290239A/en
Priority to JP8503422A priority patent/JPH10502619A/ja
Priority to FI965225A priority patent/FI965225A7/fi
Priority to HK98109815.7A priority patent/HK1009038B/en
Priority to EP95926602A priority patent/EP0771209B1/fr
Priority to AU30922/95A priority patent/AU689934B2/en
Application filed filed Critical
Priority to DE69528064T priority patent/DE69528064T2/de
Priority to PL95317872A priority patent/PL186341B1/pl
Priority to MX9700043A priority patent/MX9700043A/es
Priority to DK95926602T priority patent/DK0771209T3/da
Priority to AT95926602T priority patent/ATE223224T1/de
Priority to HU9603564A priority patent/HU220877B1/hu
Priority to RO96-02483A priority patent/RO116198B1/ro
Priority to UA97010353A priority patent/UA55371C2/uk
Publication of WO1996000503A1 publication Critical patent/WO1996000503A1/fr
Publication of WO1996000503B1 publication Critical patent/WO1996000503B1/fr
Priority to BG101077A priority patent/BG63453B1/bg
Priority to NO965592A priority patent/NO965592L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

L'invention concerne des oligopeptides comprenant des séquences d'acides aminés reconnues et clivées protéolytiquement par un antigène spécifique de la prostate (PSA). L'invention concerne également des dosages comprenant ces oligopeptides utiles pour déterminer l'activité de la protéase de PSA libre in vitro et in vivo. En outre, l'invention concerne des agents thérapeutiques comprenant des conjugués de ces oligopeptides ainsi que des agents cytotoxiques connus.
PCT/US1995/008156 1994-06-28 1995-06-07 Nouveaux peptides Ceased WO1996000503A1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
RO96-02483A RO116198B1 (ro) 1994-06-28 1995-06-07 Oligopeptida si conjugat al acesteia, clivate selectiv de antigenul specific de prostata
PL95317872A PL186341B1 (pl) 1994-06-28 1995-06-07 Oligopeptyd, sposób oznaczania aktywności proteolitycznej wolnego antygenu swoistego dla prostaty wpróbce, sposób identyfikacji związków, hamującychaktywność proteolityczną antygenu swoistego dla prostaty, oraz koniugat użyteczny do leczenia raka prostaty
NZ290239A NZ290239A (en) 1994-06-28 1995-06-07 Peptides, oligopeptides with amino acid sequences that are recognised and proteolytically cleaved by free prostate specific antigen, assays and medicaments comprising such peptides
JP8503422A JPH10502619A (ja) 1994-06-28 1995-06-07 新規ペプチド
FI965225A FI965225A7 (fi) 1994-06-28 1995-06-07 Uusia peptidejä
HK98109815.7A HK1009038B (en) 1994-06-28 1995-06-07 Novel peptides
EP95926602A EP0771209B1 (fr) 1994-06-28 1995-06-07 Nouveaux peptides
DK95926602T DK0771209T3 (da) 1994-06-28 1995-06-07 Hidtil ukendte peptider
BR9508151A BR9508151A (pt) 1994-06-28 1995-06-07 Oligopeptídeo testes para determinar a atividade proteolítica de antígeno livre específico para próstata em uma amostra e para identificar compostos que inibem atividade proteolítica de antígeno específico para próstata e conjugado
DE69528064T DE69528064T2 (de) 1994-06-28 1995-06-07 Neuartige peptide
MX9700043A MX9700043A (es) 1994-06-28 1995-06-07 Peptidos novedosos.
SK1640-96A SK164096A3 (en) 1994-06-28 1995-06-07 Oligopeptide and a conjugate containing it
AU30922/95A AU689934B2 (en) 1994-06-28 1995-06-07 Novel peptides
AT95926602T ATE223224T1 (de) 1994-06-28 1995-06-07 Neuartige peptide
HU9603564A HU220877B1 (en) 1994-06-28 1995-06-07 Novel olygopeptides, diagnostic methods for use thereof and conjugates for treatment of prostata cancer
UA97010353A UA55371C2 (uk) 1994-06-28 1995-07-06 Олігопептид, який розпізнається та протеолітично розщеплюється вільним простатичним антигеном, спосіб визначення протеолітичної активності вказаного антигену, спосіб ідентифікації сполук, які інгібують протеолітичну активність вказаного антигену, кон'югат, який використовують для лікування раку передміхурової залози
BG101077A BG63453B1 (bg) 1994-06-28 1996-12-27 Пептиди
NO965592A NO965592L (no) 1994-06-28 1996-12-27 Nye peptider

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US267,092 1994-06-28
US08/267,092 US5599686A (en) 1994-06-28 1994-06-28 Peptides
US40483395A 1995-03-15 1995-03-15
US404,833 1995-03-15

Publications (2)

Publication Number Publication Date
WO1996000503A1 WO1996000503A1 (fr) 1996-01-11
WO1996000503B1 true WO1996000503B1 (fr) 1996-02-22

Family

ID=26952210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/008156 Ceased WO1996000503A1 (fr) 1994-06-28 1995-06-07 Nouveaux peptides

Country Status (26)

Country Link
US (1) US6143864A (fr)
EP (1) EP0771209B1 (fr)
JP (1) JPH10502619A (fr)
KR (1) KR100379351B1 (fr)
CN (1) CN1156964A (fr)
AT (1) ATE223224T1 (fr)
AU (1) AU689934B2 (fr)
BG (1) BG63453B1 (fr)
BR (1) BR9508151A (fr)
CA (1) CA2192957A1 (fr)
CZ (1) CZ381096A3 (fr)
DE (1) DE69528064T2 (fr)
DK (1) DK0771209T3 (fr)
ES (1) ES2182908T3 (fr)
FI (1) FI965225A7 (fr)
HU (1) HU220877B1 (fr)
MX (1) MX9700043A (fr)
NO (1) NO965592L (fr)
NZ (1) NZ290239A (fr)
PL (1) PL186341B1 (fr)
PT (1) PT771209E (fr)
RO (1) RO116198B1 (fr)
RU (1) RU2162855C2 (fr)
SK (1) SK164096A3 (fr)
UA (1) UA55371C2 (fr)
WO (1) WO1996000503A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
CA2203622C (fr) * 1994-08-19 2011-11-01 Andre Trouet Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation
WO1997014416A1 (fr) * 1995-10-18 1997-04-24 Merck & Co., Inc. Conjugues utiles pour traiter l'adenome prostatique benin
US5952294A (en) * 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser
AU716564B2 (en) * 1996-11-06 2000-03-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Protease-activatable pseudomonas exotoxin A-like proproteins
US6504014B1 (en) 1997-05-19 2003-01-07 The John Hopkins University Tissue specific prodrug
US6545131B1 (en) 1997-05-19 2003-04-08 The Johns Hopkins University Tissue specific prodrug
WO1998052966A1 (fr) 1997-05-19 1998-11-26 The Johns Hopkins University School Of Medecine Bioprecurseurs a specificite tissulaire
US6391305B1 (en) * 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
EA002745B1 (ru) * 1997-12-02 2002-08-29 Мерк Энд Ко., Инк. Конъюгаты, которые можно использовать при лечении рака предстательной железы
AU749063B2 (en) * 1998-03-05 2002-06-20 Merck & Co., Inc. Conjugates useful in the treatment of prostrate cancer
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
EP1173223A2 (fr) 1999-04-30 2002-01-23 Slil Biomedical Corporation Nouveaux conjugues d'analogue de polyamine et conjugues de quinone, utilises pour le traitement de cancers et de maladies de la prostate
US6482943B1 (en) * 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
US6649587B1 (en) 1999-04-30 2003-11-18 Slil Biomedical Corporation Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
JP2004500553A (ja) * 1999-10-07 2004-01-08 シファーゲン　バイオシステムズ，　インコーポレイテッド 前立腺ガンのマーカータンパク質
GB9924759D0 (en) 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
RU2002127425A (ru) 2000-03-15 2004-03-27 Бристоль-Мейерз Сквибб Фарма Компани (Us) Расщепляемые пептидазой целевые противоопухолевые лекарственные средства и их терапевтическое использование
WO2001095943A2 (fr) * 2000-06-14 2001-12-20 Medarex, Inc. Composes de promedicaments contenant de l'isoleucine
AU2001297817A1 (en) 2000-11-08 2002-11-25 Eli Lilly And Company Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
EP1219634A1 (fr) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Glycoconjugués d'agents cytostatiques avec lien peptidique spécifiquement clivable
WO2002081630A2 (fr) * 2001-04-06 2002-10-17 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Utilisation de semenogeline dans le diagnostic, le pronostic et le traitement du cancer
ES2542888T3 (es) * 2001-08-24 2015-08-12 Uvic Industry Partnerships Inc. Proaerolisina que contiene secuencias de activación de proteasa y métodos de uso para el tratamiento del cáncer de próstata
JP2005510240A (ja) * 2001-11-28 2005-04-21 セローノ ジェネティクス インスティテュート ソシエテ アノニム ヒトｃＤＮＡ及びタンパク質及びその使用
US7108976B2 (en) * 2002-06-17 2006-09-19 Affymetrix, Inc. Complexity management of genomic DNA by locus specific amplification
EP1556398B1 (fr) * 2002-10-31 2009-09-09 Metabasis Therapeutics, Inc. Nouveaux promedicaments de cytarabine monophosphate
WO2005041981A1 (fr) * 2003-10-31 2005-05-12 Kurume University Traitement combine vaccin peptidique et estramustine
CN101238145B (zh) 2005-06-14 2013-04-24 普罗陶克斯有限公司 修饰的成孔蛋白在制备治疗或预防良性前列腺增生的药物中的应用
JP5278873B2 (ja) * 2008-05-14 2013-09-04 国立大学法人九州工業大学 癌診断用試薬
WO2010117768A1 (fr) * 2009-04-10 2010-10-14 The Regents Of The University Of California Antigènes associés à la prostatite et leurs méthodes d'utilisation
KR20110069618A (ko) * 2009-12-17 2011-06-23 주식회사 셀앤바이오 전립선암 진단용 키트 및 진단방법
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
JP2021509907A (ja) 2018-01-09 2021-04-08 リガンド・ファーマシューティカルズ・インコーポレイテッド アセタール化合物およびその治療的使用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4277466A (en) * 1978-08-29 1981-07-07 Institut International De Pathologie Cellulaire Et Moleculaire Complexes of DNA and esters derived from daunorubicine, their preparation and use
US4446122A (en) * 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
OA06421A (fr) * 1980-06-10 1981-09-30 Omnium Chimique Sa Procédé de préparation de dérivés N-(vinblastinoyl-23) d'acides aminés et de peptides.
EP0124502B1 (fr) * 1983-04-29 1991-06-12 OMNICHEM Société anonyme Nouveaux conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques contenant ces conjugués
JPS6034997A (ja) * 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ 生物学的活性ポリペプチド類
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
EP0126344A2 (fr) * 1983-05-20 1984-11-28 Abbott Laboratories Esters tripeptidiques d'agents thérapeutiques
FR2583983B1 (fr) * 1985-06-07 1988-05-27 Centre Nat Rech Scient Nouvelles prodrogues macromoleculaires hydrosolubles, leur preparation et leur utilisation comme medicaments notamment antitumoraux et antiparasitaires
EP0232693A3 (fr) * 1985-12-16 1988-04-06 La Region Wallonne Conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques les contenant
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5220001A (en) * 1989-10-25 1993-06-15 Zaidan Hojim Biseibutsu Dong-A Pharm Co. Anthracycline glycoside derivatives
IT1241927B (it) * 1990-05-14 1994-02-01 Menarini Farma Ind 3'-deamino-4'-deossi-4'-amino-8-fluoroantra- cicline processi per la loro preparazione e composizioni farmaceutiche che le contengono
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
SE9002480D0 (sv) * 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
EP0671412A1 (fr) * 1990-11-30 1995-09-13 Asahi Glass Company Ltd. Peptides inhibant l'infiltration de cellules tumorales et inhibiteurs de la métastase du cancer
FR2678274A1 (fr) * 1991-06-25 1992-12-31 Medgenix Group Sa N-leucyl epirubicine application a titre de medicament antitumoral et procede de preparation.
US5288612A (en) * 1991-07-03 1994-02-22 The Scripps Research Institute Assay methods for detecting serum proteases, particularly activated protein C
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DE4233152A1 (de) * 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
JPH08502889A (ja) * 1992-10-29 1996-04-02 トーマス・ジェファーソン・ユニバーシティ 前立腺癌の微小転移を検出する方法
AU6364094A (en) * 1993-03-12 1994-09-26 Board Of Regents, The University Of Texas System Anthracyclines with unusually high activity against cells resistant to doxorubicin and its analogs
GB9320191D0 (en) * 1993-09-30 1993-11-17 Univ Napier Compounds
JPH10500294A (ja) * 1994-05-10 1998-01-13 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 組換え型ｈｋ２ポリペプチド
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
CA2203622C (fr) * 1994-08-19 2011-11-01 Andre Trouet Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation
AUPM769394A0 (en) * 1994-08-25 1994-09-15 Commonwealth Scientific And Industrial Research Organisation Assay for the detection of proteases

Similar Documents

Publication Publication Date Title
WO1996000503B1 (fr) Nouveaux peptides
HUT76350A (en) Novel peptides
EP0591524A4 (fr)
Mentlein Proline residues in the maturation and degradation of peptide hormones and neuropeptides
Shapira et al. Encephalitogenic fragment of myelin basic protein: amino acid sequence of bovine, rabbit, guinea pig, monkey, and human fragments
IL128829A0 (en) Improved solid-phase peptide and agent for use in such synthesis
CA2050336A1 (fr) Systeme de traitement des levures comportant un acide amine charge negativement adjacent au site de traitement
EP1623994A3 (fr) Protection de peptides thérapeutiques endogènes contre l'activité peptidase par conjugaison de composants sanguins
EP0150126A3 (en) The synthesis of protein with an identification peptide
WO1997028247A3 (fr) PROTEINES DE RESERVE DE PLANTES ENRICHIES EN ACIDES AMINES, NOTAMMENT η-ZEINE DE MAIS ENRICHIE EN LYSINE, PLANTES EXPRIMANT CES PROTEINES
DE69109109D1 (de) Ubiquitinspezifische protease.
AU1353295A (en) Peptides derived from a retrovirus of the HIV group, and their use
AU1003888A (en) Pancreatic secretory trypsin inhibitor and variants thereof produced by a recombinant host, process, expression vector and recombinant host therefore and pharmaceutical use thereof
Angliker Synthesis of tight binding inhibitors and their action on the proprotein-processing enzyme furin
Falquet et al. A human de‐ubiquitinating enzyme with both isopeptidase and peptidase activities in vitro
De Camargo et al. Influence of the carboxyl terminus of luteinizing hormone-releasing hormone and bradykinin on hydrolysis by brain endo-oligopeptidases.
EP0528686B8 (fr) Procédé pour la production de peptides
AU6710998A (en) Process for preparing modified proteins
AU3850997A (en) Immunologically active proteins of borrelia burgdorferi, coded nuclein acids of such and their use in test kits and vaccines
Yonezawa et al. Substrate specificity of cucumisin on synthetic peptides
Bányai et al. Proximity of the catalytic region and the kringle 2 domain in the closed conformer of plasminogen
AU9083791A (en) Thrombolytic peptide, production thereof and thrombolytic agent
ATE283914T1 (de) Iga1-protease fragment als trägerpeptid
Nörenberg et al. Processing of the oxytocin precursor: isolation of an exopeptidase from neurosecretory granules of bovine pituitaries
Uddin et al. Specific cleavage of synthetic renin substrate by mouse γ-nerve growth factor